New COVID-19 Vaccine Shows Promise of Lasting Protection
Inventprise’s novel conjugate vaccine may provide long-term immunity against COVID-19 variants, potentially reducing the need for frequent booster shots. The groundbreaking preclinical findings suggest a new approach to immunization, offering a path toward more durable and equitable protection worldwide.
How the New Vaccine Works
A recent preclinical study published in the Vaccine Journal highlights the capabilities of Inventprise’s bivalent SARS-CoV-2 conjugate vaccine. The vaccine utilizes a novel platform designed to trigger a robust immune response by stimulating both B-cell (antibody-mediated) and T-cell (cellular) immunity.
Unlike existing mRNA vaccines, this conjugate vaccine is engineered to stimulate long-lasting immunity. This is achieved by linking a detoxified diphtheria-derived carrier protein (rCRM197) to the SARS-CoV-2 Beta and Delta strain surface protein. This method successfully elicited strong immune responses in preclinical models.
“We are excited to share these results, which highlight the power of conjugate vaccine platforms, not just for COVID-19, but potentially for a wide range of infectious diseases,”
—Ivan Olave, VP of Viral Vaccines, Inventprise
The study, initiated in 2022 and concluded in late 2023, demonstrates broad neutralizing antibody responses across several SARS-CoV-2 variants. It also shows evidence of both humoral and cellular immune activation. The World Health Organization reports that as of May 2024, over 1.4 billion doses of COVID-19 vaccines have been administered globally (WHO 2024).
Focus on Global Health
The conjugate vaccine platform developed by Inventprise holds potential for addressing limitations in current mRNA-based vaccine strategies. Protein conjugate vaccines, already used for diseases such as Haemophilus influenzae and pneumococcus, are recognized for their safety and durability.
This approach could be particularly beneficial in areas where cold chain requirements and the logistics of booster shots pose considerable obstacles, potentially offering a sustainable solution for equitable immunization. The company is actively seeking partnerships to further research and refine the duration of protection offered by this innovative vaccine.
Inventprise, established in 2012 by Dr. Subhash Kapre, is a clinical-stage vaccine invention company based in Redmond, Washington, with a presence in Europe. The company focuses on developing high-valency vaccines to protect against a variety of global infectious diseases.